Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
QuintilesIMS
Fuji
Deloitte
Argus Health
Covington
Johnson and Johnson
Merck
Julphar

Generated: May 24, 2018

DrugPatentWatch Database Preview

NOVOLIN 70/30 Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Novolin 70/30 patents expire, and what generic alternatives are available?

Novolin 70/30 is a drug marketed by Novo Nordisk Inc and is included in two NDAs.

The generic ingredient in NOVOLIN 70/30 is insulin recombinant human; insulin susp isophane recombinant human. There are thirty-nine drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the insulin recombinant human; insulin susp isophane recombinant human profile page.
Summary for NOVOLIN 70/30
Drug patent expirations by year for NOVOLIN 70/30

US Patents and Regulatory Information for NOVOLIN 70/30

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo Nordisk Inc NOVOLIN 70/30 insulin recombinant purified human; insulin susp isophane semisynthetic purified human INJECTABLE;INJECTION 019441-001 Jul 11, 1986 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novo Nordisk Inc NOVOLIN 70/30 insulin recombinant human; insulin susp isophane recombinant human INJECTABLE;INJECTION 019991-001 Jun 25, 1991 OTC Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Johnson and Johnson
Federal Trade Commission
AstraZeneca
Daiichi Sankyo
Boehringer Ingelheim
Medtronic
Dow
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.